Transplantation-Related Mortality, Graft Failure, and Survival after Reduced-Toxicity Conditioning and Allogeneic Hematopoietic Stem Cell Transplantation in 100 Consecutive Pediatric Recipients

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 4, 2013, Pages 552-561

  Satwani, Prakash ^a   Jin, Zhezhen ^a   Duffy, Deirdre ^b   Morris, Erin ^b   Bhatia, Monica ^a   Garvin, James H ^a   George, Diane ^a   Bradley, Mary Brigid ^a   Harrison, Lauren ^b   Petrillo, Kristen ^a   Schwartz, Joseph ^c   Foley, Sandra ^b   Hawks, Ria ^a   Baxter Lowe, Lee Ann ^d   Cairo, Mitchell S ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c NewYork Presbyterian Hospital   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bone marrow transplantation; Children; Engraftment; Overall survival; Reduced intensity conditioning regimen

Indexed keywords

METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD DONOR; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; EVENT FREE SURVIVAL; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIMARY GRAFT DYSFUNCTION; SAFETY; SCHOOL CHILD; SIBLING; SURVIVAL; UMBILICAL CORD BLOOD;

ADOLESCENT; BLOOD PLATELETS; CHILD; CHILD, PRESCHOOL; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; MALE; MYELOABLATIVE AGONISTS; NEUTROPHILS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84875514036     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.12.005     Document Type: Article

References (45)

1. Thomas E.D. Karnofsky Memorial Lecture: marrow transplantation for malignant diseases. J Clin Oncol 1983, 1:517-531.
2. Alatrash G., de Lima M., Hamerschlak N., et al. Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant 2011, 17:1490-1496.
3. Styczynski J., Tallamy B., Waxman I., et al. A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents. Bone Marrow Transplant 2011, 46:790-799.
4. Socie G., Stone J.V., Wingard J.R., et al. Late Effects Working Committee of the International Bone Marrow Transplant Registry. Long-term survival and late deaths after allogeneic bone marrow transplantation. N Engl J Med 1999, 341:14-21.
5. Styczynski J., Cheung Y.K., Garvin J., et al. Outcomes of unrelated cord blood transplantation in pediatric recipients. Bone Marrow Transplant 2004, 34:129-136.
6. Wagner J.E., Barker J.N., DeFor T.E., et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002, 100:1611-1618.
7. Wagner J.E., Rosenthal J., Sweetman R., et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 1996, 88:795-802.
8. Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2011. Available at:. http://www.cibmtr.org.
9. Shaw P.J., Kan F., Woo Ahn K., et al. Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. Blood 2010, 116:4007-4015.
10. Gluckman E., Rocha V., Boyer-Chammard A., et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997, 337:373-381.
11. Locatelli F., Rocha V., Chastang C., et al. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Eurocord-Cord Blood Transplant Group. Blood 1999, 93:3662-3671.
12. Petterson T.E., Gabriel M., Tiedemann K., et al. Outcome following unrelated cord blood transplant in 136 patients with malignant and non-malignant diseases: a report from the Australian and New Zealand Children's Haematology and Oncology Group. Bone Marrow Transplant 2009, 43:207-215.
13. Sun C.L., Francisco L., Kawashima T., et al. Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Blood 2010, 116:3129-3139.
14. Pulsipher M.A., Boucher K.M., Wall D., et al. Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. Blood 2009, 114:1429-1436.
15. Jacobsohn D.A., Duerst R., Tse W., et al. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet 2004, 364:156-162.
16. Bradley M.B., Satwani P., Baldinger L., et al. Reduced-intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases. Bone Marrow Transplant 2007, 40:621-631.
17. Del Toro G., Satwani P., Harrison L., et al. A pilot study of reduced-intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients. Bone Marrow Transplant 2004, 33:613-622.
18. Bhatia M., Militano O., Jin Z., et al. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 2010, 16:333-343.
19. Osunkwo I., Bessmertny O., Harrison L., et al. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant 2004, 10:246-258.
20. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974, 18:295-304.
21. Waxman I.M., Militano O., Baldinger L., et al. Sequential administration of sargramostim and filgrastim in pediatric allogeneic stem cell transplantation recipients undergoing myeloablative conditioning. Pediatr Transplant 2009, 13:464-474.
22. Roman E., Osunkwo I., Militano O., et al. Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation. Pediatr Blood Cancer 2008, 50:325-330.
23. Shereck E.B., Cooney E., van de Ven C., et al. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients. Pediatr Blood Cancer 2007, 49:306-312.
24. Satwani P., Baldinger L., Freedman J., et al. Incidence of viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 2009, 15:1587-1595.
25. Bacigalupo A., Ballen K., Rizzo D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009, 15:1628-1633.
26. Deeg H.J., Sandmaier B.M. Who is fit for allogeneic transplantation?. Blood 2010, 116:4762-4770.
27. Smith A.R., Majhail N.S., MacMillan M.L., et al. Hematopoietic cell transplantation comorbidity index predicts transplantation outcomes in pediatric patients. Blood 2011, 117:2728-2734.
28. Satwani P., Cooper N., Rao K., et al. Reduced-intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases. Bone Marrow Transplant 2008, 41:173-182.
29. Satwani P., Harrison L., Morris E., et al. Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: end of the beginning and future challenges. Biol Blood Marrow Transplant 2005, 11:403-422.
30. Satwani P., Morris E., Bradley M.B., et al. Reduced-intensity and non-myeloablative allogeneic stem cell transplantation in children and adolescents with malignant and non-malignant diseases. Pediatr Blood Cancer 2008, 50:1-8.
31. Claviez A., Canals C., Dierickx D., et al. Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood 2009, 114:2060-2067.
32. Strullu M., Rialland F., Cahu X., et al. Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning regimen in children: a single-center experience. Eur J Haematol 2012, 88:504-509.
33. Verneris M.R., Eapen M., Duerst R., et al. Reduced-intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2010, 16:1237-1244.
34. Geyer M.B., Jacobson J.S., Freedman J., et al. A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced-toxicity conditioning and umbilical cord blood transplantation in paediatric recipients. Br J Haematol 2011, 155:218-234.
35. Szabolcs P., Cairo M.S. Unrelated umbilical cord blood transplantation and immune reconstitution. Semin Hematol 2010, 47:22-36.
36. Kurtzberg J., Laughlin M., Graham M.L., et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996, 335:157-166.
37. Marsh R.A., Vaughn G., Kim M.O., et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood 2010, 116:5824-5831.
38. Rao K., Amrolia P.J., Jones A., et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 2005, 105:879-885.
39. Roman E., Cooney E., Harrison L., et al. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced-intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Clin Cancer Res 2005, 11:7164s-7170s.
40. Cairo M.S., Rocha V., Gluckman E., et al. Alternative allogeneic donor sources for transplantation for childhood diseases: unrelated cord blood and haploidentical family donors. Biol Blood Marrow Transplant 2008, 14:44-53.
41. Ruggeri A., Eapen M., Scaravadou A., et al. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant 2011, 17:1375-1382.
42. Couriel D.R., Saliba R.M., Giralt S., et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2004, 10:178-185.
43. Mielcarek M., Martin P.J., Leisenring W., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003, 102:756-762.
44. Remberger M., Mattsson J., Hassan Z., et al. Risk factors for acute graft-versus-host disease grades II-IV after reduced-intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study. Bone Marrow Transplant 2008, 41:399-405.
45. Liao Y., Geyer M.B., Yang A.J., et al. Cord blood transplantation and stem cell regenerative potential. Exp Hematol 2011, 39:393-412.